Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Recurrent Endometrial Carcinoma
Recurrent Renal Cell Cancer
Stage IV Endometrial Carcinoma
Stage IV Renal Cell Cancer
Endometrial Papillary Serous Carcinoma
Stage III Endometrial Carcinoma
Unspecified Adult Solid Tumor, Protocol Specific
Stage III Renal Cell Cancer

Interventions: Drug: temsirolimus
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-09-09

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01198184

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Temsirolimus

First Posted Date: 2010-09-08

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT01196429

Locations: 🇺🇸
Cadence Cancer Center in Warrenville, Warrenville, Illinois, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 142 locations

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sorafenib

First Posted Date: 2010-08-23

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 278

Registration Number: NCT01187199

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1

Withdrawn

Conditions: Brain Stem Neoplasms
Glioma
Pinealoma

First Posted Date: 2010-08-17

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01182883

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lenalidomide
Drug: Bevacizumab
Drug: Sorafenib
Drug: Temsirolimus
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-fluorouracil

First Posted Date: 2010-08-17

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01183663

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Phase 4

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2010-08-11

Last Posted Date: 2019-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT01180049

Locations: 🇷🇴
Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania
🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇺🇸
Mercy Research Institute, Miami, Florida, United States

and more 27 locations

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: vorinostat
Drug: temsirolimus
Other: laboratory biomarker analysis
Procedure: positron emission tomography/computed tomography

First Posted Date: 2010-08-03

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01174199

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1

Withdrawn

Conditions: Mantle Cell Lymphoma

First Posted Date: 2010-07-27

Last Posted Date: 2011-03-16

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 20

Registration Number: NCT01170052

Locations: 🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Charité Mitte, Berlin, Germany

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2

Terminated

Conditions: Mucosal Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: temsirolimus
Drug: selumetinib
Other: laboratory biomarker analysis

First Posted Date: 2010-07-20

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT01166126

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Recurrent Cervical Cancer
Recurrent Endometrial Carcinoma
Stage III Neuroendocrine Carcinoma of the Skin
Stage III Ovarian Epithelial Cancer
Stage IV Endometrial Carcinoma
Stage IV Neuroendocrine Carcinoma of the Skin
Stage IV Non-small Cell Lung Cancer
Stage IVA Cervical Cancer
Recurrent Gastrointestinal Carcinoid Tumor

Interventions: Drug: temsirolimus
Drug: vinorelbine ditartrate

First Posted Date: 2010-07-01

Last Posted Date: 2016-06-13

Lead Sponsor: University of Southern California

Target Recruit Count: 19

Registration Number: NCT01155258

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy